Three scientists who participated in the breakthrough discovery of embryonic stem cells and mammalian DNA recombination surface series won awards, which laid the foundation for the development of base targeting technology.
Base targeting technology allows scientists to use embryonic stem cells to inactivate or modify specific mouse bases, find out the actual functions of some bases and study the effects of some basic health diseases. Using this technology, mouse embryonic stem cells were introduced into a specific base for transformation, and some cells were injected into mouse embryos. Scientists hope to find some pathogens of intractable diseases and finally find a cure.
The first mouse modified by this method was published in 1989. Members of the Nobel Committee said that using this technology, about 10000 mice have been studied for the same base, and about half of rodents have the same base.
Base targeting technology has penetrated into all fields of biopharmaceuticals, and its effect of base analysis function and similar production benefits continue. It has been widely used to help scientists use mice to study diseases, such as heart disease, diabetes, cancer and cystic fibrosis.